Psoriatic Arthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For the Risankizumab-Exposed Group:
- People who currently live in the United States
- People who are currently pregnant
- People who have been diagnosed with plaque psoriasis, psoriatic arthritis, Crohn's disease, or another condition for which the drug risankizumab is FDA-approved
- People who received at least one dose of risankizumab during their pregnancy, or within 20 weeks before becoming pregnant
For the Comparison Group (similar disease, different medication):
- People who currently live in the United States
- People who are currently pregnant
- People who have been diagnosed with plaque psoriasis, psoriatic arthritis, Crohn's disease, or another condition for which risankizumab is FDA-approved
- People who received at least one dose of a related type of medication (such as TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, or other IL-23 inhibitors) during pregnancy or shortly before pregnancy (confirm exact timing with trial site)
Who may not be able to join:
For the Risankizumab-Exposed Group:
- People who also received a related medication (such as TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, or other IL-23 inhibitors) at any point during pregnancy or shortly before
- People whose pregnancy has already ended before registering for the study
For the Comparison Group:
- People who received risankizumab at any point during pregnancy or within 20 weeks before becoming pregnant
- People whose pregnancy has already ended before registering for the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: 1-877-302-2161
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants with Major Congenital Malformation (MCM)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.